Literature DB >> 6453159

In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity.

M T Lotze, S A Rosenberg.   

Abstract

Supernatants containing T cell growth factor (TCGF) that are produced by incubating human peripheral blood lymphocytes with the mitogenic lectin, phytohemagglutinin (PHA) have previously been shown to allow the successful culture of antigen-reactive T cells. The continued presence of PHA in these preparations, however, complicates the analysis of the direct effects of TCGF. In this report we describe in detail methods used to remove greater than 99% of the exogenous mitogen with a 77% yield of TCGF. TCGF activity precipitated between 50 and 75% saturated ammonium sulfate and was freed of 90% of exogenous PHA. Residual PHA was removed by absorption on affinity columns of Sepharose 4B linked to rabbit anti-PHA antibody. Ninety-nine percent of PHA was removed by these techniques based on assays of the mitogenesis of fresh lymphoid cells and the use of tracer quantities of highly purified radiolabeled PHA. This partially purified TCGF (PP-TCGF) supported the continued growth of mitogen or alloactivated lymphoid cells but not fresh resting cells unless high starting numbers of lymphoid cells are used. An increase of up to 500 times the number of specific lytic units/culture was obtained by expanding alloactivated cells in PP-TCGF when compared to the crude TCGF supernatants.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6453159

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

2.  Growth of antigen specific, HLA restricted T lymphocyte clones from cerebrospinal fluid.

Authors:  B Fleischer; U Bogdahn
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

3.  Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.

Authors:  A Mazumder; E A Grimm; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Is there correlation of T cell proliferative functions and surface marker phenotypes in patients with acquired immune deficiency syndrome or lymphadenopathy syndrome?

Authors:  J C Gluckman; D Klatzmann; M Cavaille-Coll; E Brisson; A Messiah; D Lachiver; W Rozenbaum
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

5.  Molecular cloning of human interleukin 2 cDNA and its expression in E. coli.

Authors:  R Devos; G Plaetinck; H Cheroutre; G Simons; W Degrave; J Tavernier; E Remaut; W Fiers
Journal:  Nucleic Acids Res       Date:  1983-07-11       Impact factor: 16.971

6.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

7.  Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

Authors:  E A Grimm; R J Robb; J A Roth; L M Neckers; L B Lachman; D J Wilson; S A Rosenberg
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

8.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

9.  IL-2-mediated T cell proliferation in humans is blocked by a monoclonal antibody directed against monomorphic determinants of HLA-DR antigens.

Authors:  A Moretta; R S Accolla; J C Cerottini
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

10.  Production of interleukin-2 (IL-2) and expression of IL-2 receptor in patients with IgA nephropathy.

Authors:  T W Lee; M J Kim
Journal:  Korean J Intern Med       Date:  1992-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.